Clinical trials
Neoplasms clinical trials
Below are recruiting neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,691 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06657131Recruiting
PSMA PET scan for prostate cancer recurrence
This trial looks at how well a special PET scan (called PSMA PET) can find prostate cancer that has come back after treatment. It uses a radioactive tracer to spot cancer cells. Your doctor may already have ordered this scan as part of your regular care.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT06667726RecruitingPhase 2
New PET scan for better brain tumor care
This trial studies a special PET scan called 18F-DOPA PET/CT to see if it can help doctors better manage brain tumors. It may be used before surgery, for radiation planning, or when MRI results are unclear.
Rochester, MinnesotaAges 18 years+ - NCT06672302Recruiting
Blood test to find high breast cancer risk
This study uses a blood test to help identify women who are at high risk for breast cancer. It is for Korean women aged 40 or older who have a suspicious breast finding and need a biopsy.
SeoulAges 40 years+ - NCT06672887RecruitingPhase 2/Phase 3
Helping employers support cancer survivors' return to work
This trial tests a program called MiLES that helps employers support employees with cancer to return to work. It is for people who have been diagnosed with cancer less than 2 years ago, are currently on sick leave, and are working with their employer and a company doctor or reintegration consultant.
ArnhemAges 18–65 - NCT06675643Recruiting
Remote monitoring of side effects from melanoma treatment
This study tests a smartphone app called Vigilant that helps monitor side effects from a melanoma treatment (ipilimumab and nivolumab). You may be able to join if you are about to start this therapy.
Rochester, MinnesotaAges 18 years+ - NCT06686394RecruitingPhase 1/Phase 2
New drug combo for HER2+ breast cancer that has spread
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
Aurora, ColoradoAges 18 years+ - NCT06688188RecruitingEarly Phase 1
Study of 68Ga-JH12 PET/CT scan in solid tumors
This trial tests a new imaging agent, 68Ga-JH12, used during a PET/CT scan to see how it spreads through the body and how much radiation it gives off. It is for people with solid tumors who want to help researchers understand this better.
Fuzhou, FujianAges 18–80 - NCT06688305RecruitingEarly Phase 1
First human test of new PET scan agent for solid tumors
This trial tests a new imaging agent called 68Ga-NI-FAPI to see how well it works in a PET scan for people with different types of solid tumors. The goal is to help doctors better see and understand tumors.
Fuzhou, FujianAges 18–80 - NCT06690827RecruitingPhase 1
Cd123-targeted car-nk cells for relapsed aml or bpdcn
This trial tests a new treatment using your own immune cells (natural killer cells) that are modified to find and attack cancer cells with a marker called CD123. It is for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard therapies.
Wuhan, HubeiAges 18–75 - NCT06695494Recruiting
Genomic testing for cancer of unknown primary
This trial is for people with cancer of unknown primary (CUP), meaning cancer that started in an unknown place in the body. It aims to use advanced genomic testing (looking at your tumor's DNA) on your stored tumor sample and blood to find clues about where the cancer began and possible treatment options.
Manchester, Greater ManchesterAges 16 years+ - NCT06702683Recruiting
Sintilimab blood levels in advanced stomach cancer
This study looks at how the amount of Sintilimab in your blood relates to how well it works and what side effects you might have. If you have advanced stomach cancer and are planning to get Sintilimab, this trial could help your doctor find the best dose for you.
Nanjing, JiangsuAges 18 years+ - NCT06702800Recruiting
Using tumor models to predict breast cancer drug response
This study uses a personal lab-grown model of your tumor (called an organoid) to help predict which drugs are most likely to work for your specific breast cancer. It is open to both early-stage and advanced breast cancer patients who are about to start or are already receiving treatment.
Changsha, HunanAges 18–70 - NCT06706700Recruiting
Biomarkers to predict cancer risk in pancreatic IPMN
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
Milan, ItalyAges 18 years+ - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Los Angeles, CaliforniaAges 1–21 - NCT06043713RecruitingPhase 1
T-cell therapy for KRAS G12V solid tumors
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Seattle, WashingtonAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Huntsville, AlabamaAges 18 years+ - NCT07587086Recruiting
PET/MR scan for breast cancer using fluorocholine
This study uses a special imaging scan (PET/MR) with a tracer called fluorocholine to see if it can help evaluate breast cancer before treatment or before surgery. It is for women who are newly diagnosed with breast cancer and will either have chemotherapy before surgery or go straight to surgery.
Taipei, TaiwanAges 25–75 - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Sarasota, FloridaAges 18 years+ - NCT06750094RecruitingPhase 3
Study of amivantamab plus FOLFIRI in colorectal cancer
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
Chandler, ArizonaAges 18 years+ - NCT07117214RecruitingPhase 1
Study of a new imaging agent for breast and lung cancers
This trial tests a new imaging agent called [68Ga]Ga-DWJ155 to see how well it helps detect certain types of advanced breast cancer and non-small cell lung cancer. It may help doctors better understand the cancer and guide treatment decisions.
Groningen, Provincie GroningenAges 18–100 - NCT07525141RecruitingPhase 1
Testing JNJ-1761981 for advanced solid tumors
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
Jacksonville, FloridaAges 18 years+ - NCT07227415RecruitingPhase 1/Phase 2
Study of a new drug for advanced kidney cancer
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT07406282Recruiting
Darolutamide for new prostate cancer that spread
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
Cleveland, OhioAges 18 years+ - NCT06714903Recruiting
Gut bacteria and immunotherapy for advanced colon cancer
This study looks at how the bacteria in your gut might affect how well immunotherapy works for advanced colorectal cancer that has spread. It aims to find out if certain gut bacteria can help make treatment more effective.
Changchun, JilinAges 35–75
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neoplasms?
- Yes. Clin2 currently lists 1,691 recruiting neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.